StocksFundsScreenerSectorsWatchlists
BIO

BIO - Bio-Rad Laboratories Inc Stock Price, Fair Value and News

279.45USD-1.57 (-0.56%)Market Closed

Market Summary

BIO
USD279.45-1.57
Market Closed
-0.56%

BIO Stock Price

View Fullscreen

BIO RSI Chart

BIO Valuation

Market Cap

8.2B

Price/Earnings (Trailing)

-12.81

Price/Sales (Trailing)

3.06

EV/EBITDA

-11.19

Price/Free Cashflow

37.4

BIO Price/Sales (Trailing)

BIO Profitability

EBT Margin

-31.82%

Return on Equity

-7.29%

Return on Assets

-5.18%

Free Cashflow Yield

2.67%

BIO Fundamentals

BIO Revenue

Revenue (TTM)

2.7B

Rev. Growth (Yr)

-6.72%

Rev. Growth (Qtr)

7.77%

BIO Earnings

Earnings (TTM)

-637.3M

Earnings Growth (Yr)

-57.75%

Earnings Growth (Qtr)

228.97%

Breaking Down BIO Revenue

Last 7 days

-7.0%

Last 30 days

-16.9%

Last 90 days

-8.9%

Trailing 12 Months

-39.1%

How does BIO drawdown profile look like?

BIO Financial Health

Current Ratio

5.83

Debt/Equity

0.14

Debt/Cashflow

0.31

BIO Investor Care

Buy Backs (1Y)

1.93%

Diluted EPS (TTM)

-21.49

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20232.8B2.8B2.7B2.7B
20222.9B2.9B2.8B2.8B
20212.7B2.9B3.0B2.9B
20202.3B2.3B2.4B2.5B
20192.3B2.3B2.3B2.3B
20182.2B2.3B2.3B2.3B
20172.1B2.1B2.1B2.2B
20162.0B2.0B2.1B2.1B
20152.1B2.1B2.0B2.0B
20142.1B2.2B2.2B2.2B
20132.1B2.1B2.1B2.1B
20122.1B2.1B2.0B2.1B
20112.0B2.0B2.1B2.1B
20101.8B1.9B1.9B1.9B
200901.8B1.8B1.8B
20080001.8B
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022


Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Which funds bought or sold BIO recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 18, 2024
Diversified Trust Co
added
259
1,525,000
2,060,350
0.06%
Apr 18, 2024
Oak Thistle LLC
sold off
-100
-617,689
-
-%
Apr 18, 2024
VAUGHAN NELSON INVESTMENT MANAGEMENT, L.P.
added
32.38
613,000
2,079,000
0.02%
Apr 18, 2024
SJS Investment Consulting Inc.
unchanged
-
69.00
1,038
-%
Apr 18, 2024
Aspire Private Capital, LLC
unchanged
-
184
2,767
-%
Apr 18, 2024
Capital Advisors, Ltd. LLC
added
3.23
1,000
11,000
-%
Apr 18, 2024
Hexagon Capital Partners LLC
unchanged
-
1,654
24,903
0.01%
Apr 18, 2024
BKM Wealth Management, LLC
sold off
-100
-18,081
-
-%
Apr 18, 2024
STATE OF MICHIGAN RETIREMENT SYSTEM
unchanged
-
132,135
1,988,750
0.01%
Apr 18, 2024
MV CAPITAL MANAGEMENT, INC.
reduced
-6.67
-2.00
9,685
-%

1–10 of 50

Are Funds Buying or Selling BIO?

Are funds buying BIO calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own BIO
No. of Funds

Unveiling Bio-Rad Laboratories Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 11, 2024
vanguard group inc
10.36%
2,427,137
SC 13G/A
Feb 13, 2024
vanguard group inc
9.93%
2,389,889
SC 13G/A
Jan 29, 2024
blackrock inc.
6.1%
1,466,226
SC 13G/A
Feb 09, 2023
vanguard group inc
9.66%
2,391,436
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 01, 2023
blackrock inc.
6.4%
1,582,313
SC 13G/A
Apr 11, 2022
schwartz alice n
89.7%
4,555,452
SC 13D/A
Feb 09, 2022
fmr llc
-
0
SC 13G/A
Feb 09, 2022
vanguard group inc
9.21%
2,287,465
SC 13G/A
Feb 01, 2022
blackrock inc.
7.1%
1,768,081
SC 13G/A

Recent SEC filings of Bio-Rad Laboratories Inc

View All Filings
Date Filed Form Type Document
Apr 17, 2024
3
Insider Trading
Apr 10, 2024
8-K
Current Report
Mar 27, 2024
ARS
ARS
Mar 27, 2024
DEF 14A
DEF 14A
Mar 20, 2024
8-K
Current Report
Mar 12, 2024
4
Insider Trading
Mar 12, 2024
4
Insider Trading
Mar 12, 2024
4
Insider Trading
Mar 12, 2024
4
Insider Trading
Mar 12, 2024
4
Insider Trading

Peers (Alternatives to Bio-Rad Laboratories Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
186.2B
40.1B
-3.77% -2.76%
32.53
4.64
-8.12% -17.45%
67.7B
19.5B
-1.53% -10.57%
53.87
3.47
4.02% -22.04%
22.5B
3.9B
-9.16% -15.16%
50.45
5.81
3.42% 23.09%
20.0B
14.8B
-5.62% -8.72%
7.55
1.35
2.12% 209.17%
MID-CAP
9.2B
3.5B
-0.49% 17.01%
32.32
2.64
4.97% 18.89%
9.1B
12.3B
-5.22% -14.61%
21.9
0.74
-2.44% -22.68%
8.2B
2.7B
-16.90% -39.13%
-12.81
3.06
-4.68% 82.43%
6.3B
4.0B
-8.41% -25.34%
-47.02
1.6
1.10% 85.84%
3.4B
366.4M
-2.66% 12.41%
-562.39
9.32
33.86% 89.83%
2.3B
6.6B
-4.93% -3.92%
12.04
0.35
2.78% -0.87%
SMALL-CAP
1.2B
3.2B
-14.38% -20.49%
-1.83
0.39
7.73% -1066.14%
383.3M
166.7M
0.86% -5.21%
-4.64
2.3
6.67% -456.34%
250.3M
324.0M
11.81% -29.38%
-1.3
0.77
-3.19% -337.41%
45.7M
52.3M
-28.65% -55.25%
-2.44
0.87
17.61% 19.28%
3.8M
3.7M
-10.98% 147.46%
-0.31
1.02
5.77% 8.23%

Bio-Rad Laboratories Inc News

Latest updates
MarketBeat5 hours ago
MarketBeat18 Apr 202405:17 pm
Yahoo Finance18 Apr 202402:03 pm
Yahoo Movies Canada18 Apr 202409:42 am

Bio-Rad Laboratories Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue7.8%681632681677730681691700733747716727790647537572625561573554617
Gross Profit9.1%366336363362397373395403400437401401460367293317330307308312333
  S&GA Expenses3.0%207201208226212211208197222216213226218198189194214202201208214
  R&D Expenses46.8%64.0044.0065.0075.0066.0067.0064.0060.0059.0064.0063.0074.0057.0060.0052.0049.0057.0048.0050.0048.0053.00
EBITDA Margin-488.9%-0.30*-0.05*-0.17*-0.07*-1.67*-2.78*--0.08*1.86*2.87*1.82*2.02*1.99*1.97*1.17*0.94*1.05*0.30*0.60*0.41*0.30*
Interest Expenses-0.3%12.0012.0012.0012.0012.0012.0011.004.000.000.000.000.005.006.006.006.006.006.006.006.006.00
Income Taxes155.0%79.0031.00-33816.00264-44.51-295-1,000-4611,094243320242370280213146-76.40171262-212
Earnings Before Taxes212.5%428137-1,50085.001,091-207-1,220-4,368-2,0275,0221,1571,2971,0891,6851,246899699-3357701,127-1,041
EBT Margin-362.4%-0.32*-0.07*-0.19*-0.09*-1.68*-2.79*-0.90*-0.07*1.86*2.87*1.82*1.97*1.93*1.90*1.09*0.87*0.98*0.23*0.53*0.34*0.22*
Net Income229.0%350106-1,16269.00828-162-925-3,367-1,5723,9309179808391,315966686554-258599865-828
Net Income Margin-307.4%-0.24*-0.06*-0.15*-0.07*-1.29*-2.15*-0.67*-0.03*1.46*2.24*1.41*1.52*1.50*1.48*0.85*0.68*0.76*0.16*0.40*0.25*0.16*
Free Cashflow-27.8%39.0054.0063.0062.0045.00-16.5436.0017.0011519613194.0024511674.0041.0013869.0013319.0051.00
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets3.4%12,29911,89611,97813,66713,50212,05812,68214,37417,79919,95315,11813,93312,97312,02110,0978,6848,0097,1777,6476,8635,611
  Current Assets-3.1%3,0483,1473,1393,2773,1583,1403,2503,3031,9902,4662,2892,1752,1402,3242,1332,0832,1802,0482,0882,0322,023
    Cash Equivalents-11.8%404458390464434518597802471860733673667840608604663561581456434
  Inventory0.6%781776777753719686657605572589599605622640628557554588590590584
  Net PPE-529---499---512---491--486499496499503509
  Goodwill1.6%414407412408406400347346347292292292292292292264264264235231220
Liabilities2.2%3,5583,4803,5313,9043,8863,6053,7604,1914,1144,6213,5233,3243,0933,1962,7442,3912,2542,0462,1601,9991,591
  Current Liabilities-6.3%523558582590569571614648681650587610632987927869905434446444451
  Long Term Debt0.0%1,1991,1991,1981,1981,1981,1971,1971,19711.0011.0011.0011.0012.0012.0012.0012.0014.00438438438439
    LT Debt, Non Current-100.0%-1,1991,1981,1981,1981,1971,1971,19711.0011.0011.0011.0012.0012.0012.0012.0014.00438438438439
Shareholder's Equity3.9%8,7418,4168,4479,7649,6158,4778,94510,20313,68515,33211,59510,6099,8908,8257,3536,2935,7575,1315,4874,8644,020
  Retained Earnings3.9%9,2618,9118,8059,9679,8989,0479,21010,13813,52515,08111,15910,2459,2688,4297,1236,1575,4714,9175,1854,5863,722
  Additional Paid-In Capital2.2%449439474463447431472459442421460445429412429424410396411403394
Accumulated Depreciation-----1,009---1,002---961--876883851850828818
Shares Outstanding0.4%29.0029.0029.0030.0030.0030.0030.0030.0030.0030.0030.0030.0030.0030.0030.0030.0030.0030.0030.0030.0030.00
Float---7,746---68.00---13,641---9,502---6,613--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations-17.1%81,00097,71598,06698,11979,61010,99053,30650,494170,900230,366154,624113,610294,400135,70092,09262,808159,80299,750155,44542,900104,994
  Share Based Compensation--------------10,800---9,100---
Cashflow From Investing860.0%72,197-9,50027,984-70,473-58,552-88,419-144,481-916,141-567,427-81,350-100,277-48,327-59,75390,854-88,573-12,422-61,196-109,909-15,071-22,713-54,811
Cashflow From Financing-654.3%-200,620-26,598-202,7384,309-86,619-8,772-121,3261,190,2934,635-15,5822,865-47,347-421,884439-2,979-98,617-4,783-4,491-15,6452,161-47,003
  Buy Backs838.0%200,00021,321--90,679-125,000----49,998--1.00-100,0058,0004,99915,001-48,912

BIO Income Statement

2023-12-31
Consolidated Statements of Income - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended12 Months Ended
Dec. 31, 2023
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Dec. 31, 2022
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]           
Net sales$ 681,200$ 632,100$ 681,100$ 676,800$ 730,300$ 680,800$ 691,100$ 700,100$ 2,671,262$ 2,802,249$ 2,922,545
Cost of goods sold        1,244,3161,234,9191,284,449
Gross profit366,300335,700362,500362,400397,100372,600395,000402,6001,426,9461,567,3301,638,096
Selling, general and administrative expense        841,723827,825877,122
Research and development expense        247,427256,889260,638
Income from operations        337,796482,616500,336
Interest expense        49,43938,1141,551
Foreign currency exchange (gains) losses, net        (7,347)(205)2,753
(Gains) losses from change in fair market value of equity securities and loan receivable        1,252,2515,193,554(4,926,248)
Other income, net        (106,443)(44,574)(26,775)
Net income (loss) before income taxes        (850,104)(4,704,273)5,449,055
Benefit from (Provision for) income taxes        212,7801,076,738(1,194,798)
Net income (loss)$ 349,700$ 106,300$ (1,162,300)$ 69,000$ 827,700$ (162,800)$ (925,100)$ (3,367,300)$ (637,324)$ (3,627,535)$ 4,254,257
Basic earnings (loss) per share:           
Net income (loss) per basic share (in dollars per share)$ 12.15$ 3.65$ (39.59)$ 2.33$ 27.89$ (5.48)$ (31.05)$ (112.50)$ (21.82)$ (121.79)$ 142.61
Weighted average common shares - basic (in shares)        29,20929,78529,831
Diluted earnings (loss) per share:           
Net income (loss) per diluted share (in dollars per share)$ 12.14$ 3.64$ (39.59)$ 2.32$ 27.78$ (5.48)$ (31.05)$ (112.50)$ (21.82)$ (121.79)$ 140.83
Weighted average common shares - diluted (in shares)        29,20929,78530,208

BIO Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 403,815$ 434,215
Short-term investments1,203,3271,356,457
Restricted investments5,5605,560
Restricted investments489,017494,645
Inventory780,517719,316
Prepaid expenses140,040124,179
Other current assets26,05423,604
Total current assets3,048,3303,157,976
Property, plant and equipment, net529,007498,612
Operating lease right-of-use assets194,730180,952
Goodwill, net413,569406,488
Purchased intangibles, net320,514332,147
Other investments7,698,0708,830,892
Other assets94,85094,599
Total assets12,299,07013,501,666
Current liabilities:  
Accounts payable144,625135,041
Accrued payroll and employee benefits139,929194,790
Current maturities of long-term debt and notes payable486465
Income and other taxes payable35,75932,428
Current operating lease liabilities40,37936,336
Other current liabilities161,621169,648
Total current liabilities522,799568,708
Long-term debt, net of current maturities1,199,0521,197,716
Deferred income taxes1,475,4951,770,481
Operating lease liabilities165,478153,597
Other long-term liabilities195,113195,912
Total liabilities3,557,9373,886,414
Commitments and contingent liabilities
Stockholders’ equity:  
Additional paid-in capital449,075447,454
Class A treasury stock at cost, 1,747,438 shares at 2023 and 640,492 shares at 2022(632,536)(263,586)
Retained earnings9,260,6299,898,203
Accumulated other comprehensive loss(336,038)(466,822)
Total stockholders’ equity8,741,1339,615,252
Total liabilities and stockholders’ equity12,299,07013,501,666
Common Class A  
Stockholders’ equity:  
Common stock22
Common Class B  
Stockholders’ equity:  
Common stock$ 1$ 1
BIO
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
 CEO
 WEBSITEbio-rad.com
 INDUSTRYMedical Instruments & Supplies
 EMPLOYEES8200

Bio-Rad Laboratories Inc Frequently Asked Questions


What is the ticker symbol for Bio-Rad Laboratories Inc? What does BIO stand for in stocks?

BIO is the stock ticker symbol of Bio-Rad Laboratories Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Bio-Rad Laboratories Inc (BIO)?

As of Fri Apr 19 2024, market cap of Bio-Rad Laboratories Inc is 8.16 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BIO stock?

You can check BIO's fair value in chart for subscribers.

What is the fair value of BIO stock?

You can check BIO's fair value in chart for subscribers. The fair value of Bio-Rad Laboratories Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Bio-Rad Laboratories Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BIO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Bio-Rad Laboratories Inc a good stock to buy?

The fair value guage provides a quick view whether BIO is over valued or under valued. Whether Bio-Rad Laboratories Inc is cheap or expensive depends on the assumptions which impact Bio-Rad Laboratories Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BIO.

What is Bio-Rad Laboratories Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 19 2024, BIO's PE ratio (Price to Earnings) is -12.81 and Price to Sales (PS) ratio is 3.06. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BIO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Bio-Rad Laboratories Inc's stock?

In the past 10 years, Bio-Rad Laboratories Inc has provided 0.085 (multiply by 100 for percentage) rate of return.